Tadalafil Tablet, Film Coated
Product Images NDC 68382-896

13 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68382-896). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 01)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 01)
Chemical structure of Tadalafil, a prescription oral tablet medication by Zydus Pharmaceuticals USA Inc. The diagram shows the molecular arrangement including fused rings and functional groups of the active ingredient Tadalafil.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 02)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 02)
A set of four line graphs displaying blood pressure changes over time (0 to 96 hours) comparing Tadalafil versus placebo. The graphs show differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, measured in mmHg, with error bars indicating variability at each time point.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 03)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 03)
Two line graphs showing the effects on standing and supine systolic blood pressure (mmHg) over 24 hours post-dose for Tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg. The vertical axis measures blood pressure change in mmHg, while the horizontal axis represents time post-dose in hours.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 04)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 04)
A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo with doxazosin. Four groups are compared: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin. The y-axis represents systolic BP change, and the x-axis shows time in hours after administration.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 05)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 05)
A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens. It compares a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days. The graph includes mean concentrations and error bars over a 120-hour period.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 06)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 06)
Line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil 5 mg to placebo. The graph shows a greater decrease in score for Tadalafil 5 mg, with data points at 0, 4, 8, and 12 weeks. Statistical significance (p<0.01) is indicated for the differences observed.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 07)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 07)
A line chart showing the change from baseline in IPSS total score over a treatment duration of 0 to 12 weeks. The graph compares Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles), with p<0.01 indicated for statistical significance. Tadalafil shows a larger decrease in IPSS score over time compared to placebo.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 08)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 08)
A line chart showing least-squares mean change from baseline over 26 weeks of therapy for two groups: Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the least-squares mean change from baseline, ranging from 0.0 to -7.0. The chart includes statistical significance markers at various points with annotations for p-values less than 0.001 and 0.05.*
FDA Label Image

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 09)

Tadalafil Tablets (5a958db7 5c0e 4cf0 9227 230886cf9bf8 09)
A line graph comparing change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in score. Tadalafil 5 mg shows a greater decrease in score over time compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*
FDA Label Image

2.5 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 10)

2.5 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 10)
Tadalafil Tablets USP 2.5 mg film-coated oral tablets packaging label. The label indicates the tablets should not be split and the entire dose taken. The package contains 30 tablets, labeled as Rx only. Manufactured by Zydus Lifesciences Ltd. in India and distributed by Zydus Pharmaceuticals USA Inc.*
FDA Label Image

5 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 11)

5 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 11)
Tadalafil Tablets USP 5 mg film-coated tablets packaging label from Zydus Pharmaceuticals USA Inc. The label states 30 tablets per package, with a warning that tablets should not be split and the entire dose should be taken. It includes storage instructions, child-resistant packaging notice, and manufacturer information from Zydus Lifesciences Ltd, Ahmedabad, India.*
FDA Label Image

10 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 12)

10 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 12)
Label for Tadalafil Tablets, USP 10 mg film-coated tablets by Zydus Pharmaceuticals USA Inc. The label shows 30 tablets per package with a note that tablets should not be split. It includes drug storage instructions, child-resistant packaging warning, manufacturer Zydus Lifesciences Ltd., and distributor information for Zydus Pharmaceuticals USA Inc.*
FDA Label Image

20 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 13)

20 mg (5a958db7 5c0e 4cf0 9227 230886cf9bf8 13)
Tadalafil Tablets USP, 20 mg film-coated oral tablets in a 30-tablet package. Label includes dosing instructions, child-resistant packaging notice, storage conditions, and manufacturer information. Distributed by Zydus Pharmaceuticals (USA) Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.